| Autor: |
Aaron Wetten, Laura Ogle, George Mells, Vinod S. Hegade, Laura Jopson, Margaret Corrigan, Jeremy Palmer, Maja Johansson, Torbjörn Bäckström, Magnus Doverskog, David E. J. Jones, Jessica K. Dyson |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Canadian Journal of Gastroenterology and Hepatology, Vol 2022 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2291-2797 |
| DOI: |
10.1155/2022/3618090 |
| Popis: |
Background and Aims. A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment. Allopregnanolone, a neurosteroid, is a positive allosteric modulator of gamma-aminobutyricacid-A (GABA-A) receptors, associated with disordered mood, cognition, and memory. This study explored associations between allopregnanolone and a disease-specific QOL scoring system (PBC-40) in PBC patients. Method. Serum allopregnanolone levels were measured in 120 phenotyped PBC patients and 40 age and gender-matched healthy controls. PBC subjects completed the PBC-40 at recruitment. Serum allopregnanolone levels were compared across PBC-40 domains for those with none/mild symptoms versus severe symptoms. Results. There were no overall differences in allopregnanolone levels between healthy controls (median = 0.03 ng/ml (IQR = 0.025)) and PBC patients (0.031 (0.42), p=0.42). Within the PBC cohort, higher allopregnanolone levels were observed in younger patients (r (120) = −0.53, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text